Share Twitter LinkedIn Facebook Email Primo N. Lara, Jr., MD, explains how he decides which metastatic renal cell carcinoma (mRCC) patients should receive a TKI as 1st line therapy Advertisement
Alcohol Consumption and Cancer Risk: Insights from the 2025 Surgeon Generalโs Advisory Breast Cancer 3 Mins Read
Genitourinary Cancer [2025] Treatment Breakthroughs: ASCO GU 2025 Highlights Nataliya Mar, MD – MOASC Genitourinary 6 Mins Read
